Top Page
Mayne Pharma Group
(OTC:MYX)
Mayne Pharma Group (MYX) vs. iShares MSCI Australia ETF (EWA)
Mayne Pharma Group Business Overview & Revenue Model
Mayne Pharma Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 408.10M | 388.15M | 183.59M | 157.15M | 400.78M | 456.99M |
| Gross Profit | 247.27M | 218.53M | 26.84M | 23.75M | 127.02M | 140.94M |
| EBITDA | 42.08M | -116.93M | -193.80M | -78.88M | -182.40M | -34.03M |
| Net Income | -93.84M | -174.23M | -316.42M | -281.29M | -208.42M | -92.79M |
Balance Sheet | ||||||
| Total Assets | 1.01B | 1.14B | 1.25B | 1.30B | 1.48B | 1.84B |
| Cash, Cash Equivalents and Short-Term Investments | 100.40M | 149.28M | 229.24M | 97.08M | 98.35M | 138.19M |
| Total Debt | 41.27M | 38.82M | 47.51M | 413.67M | 346.82M | 398.05M |
| Total Liabilities | 644.32M | 688.99M | 613.77M | 764.89M | 706.56M | 799.91M |
| Stockholders Equity | 370.28M | 454.19M | 634.36M | 545.88M | 768.36M | 1.04B |
Cash Flow | ||||||
| Free Cash Flow | 5.19M | -36.16M | -262.71M | -28.47M | 22.16M | 52.66M |
| Operating Cash Flow | 17.47M | -15.30M | -43.12M | -16.62M | 47.26M | 99.78M |
| Investing Cash Flow | -68.07M | 53.45M | 473.49M | -28.53M | -49.25M | -55.87M |
| Financing Cash Flow | -4.00M | -19.85M | -431.48M | 37.01M | -28.83M | 4.52M |
Mayne Pharma Group Technical Analysis
Mayne Pharma Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | AU$471.97M | 30.05 | 22.84% | 0.71% | 21.47% | 89.09% | |
| ― | $412.14M | ― | -35.86% | ― | ― | -19.21% | |
| ― | AU$1.82B | ― | -54.37% | ― | ― | -29.93% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$309.10M | ― | -83.97% | ― | 1271.12% | 36.87% | |
| ― | AU$81.13M | ― | -31.98% | ― | 34.20% | -23.90% | |
| ― | AU$371.29M | ― | -21.13% | ― | 5.07% | 46.14% |
Mayne Pharma Group Corporate Events
Mayne Pharma Group Limited has announced updates regarding the Foreign Investment Review Board (FIRB) approval and the proposed scheme of arrangement for Cosette Australia BidCo Pty Ltd to acquire all shares in the company. The Supreme Court of New South Wales has rescheduled the hearing to approve this scheme to 18 November 2025, pending FIRB approval. The FIRB has extended its statutory deadline, and if approval is received before 14 November 2025, Mayne Pharma may request an earlier court date. Shareholders have the right to oppose the scheme at the court hearing, which is crucial for the acquisition process and could significantly impact Mayne Pharma’s future operations and market positioning.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited is facing potential challenges in its proposed acquisition by Cosette Pharmaceuticals, as the Australian Treasurer has expressed preliminary concerns that the acquisition may not be in the national interest due to potential negative impacts on the Australian economy and community. The Treasurer is particularly concerned about the potential closure of Mayne Pharma’s manufacturing site in Adelaide, which plays a significant role in Australia’s pharmaceutical manufacturing and research capabilities. Mayne Pharma has invested heavily in this site and disagrees with the commercial rationale for its closure. The company is actively engaging with Cosette to address these concerns and expedite the approval process, while also keeping shareholders informed of developments.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$6.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has announced the cessation of 5,503 performance rights due to unmet conditions, as of October 28, 2025. This announcement may impact the company’s operational strategy and stakeholder interests, reflecting a potential shift in how performance incentives are managed within the organization.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$6.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
UBS Group AG and its related bodies corporate have ceased to be substantial shareholders of Mayne Pharma Group Limited as of October 16, 2025. This change in shareholder status may impact Mayne Pharma’s market dynamics and investor relations, as substantial shareholders often have significant influence over company decisions.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$6.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited announced the cessation of 8,311 performance rights due to the lapse of conditional rights that were not satisfied. This announcement may impact the company’s capital structure and could have implications for stakeholders regarding the company’s performance and strategic goals.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited announced a delay in the Foreign Investment Review Board’s decision regarding its acquisition by Cosette Pharmaceuticals, which may affect the timing of the Second Court Hearing initially scheduled for 22 October 2025. The company is assessing whether to reschedule the hearing and will update stakeholders accordingly, though shareholders are not required to take any action at this time.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has announced a court hearing to approve a proposed scheme of arrangement, where Cosette Australia BidCo Pty Ltd will acquire 100% of Mayne Pharma’s shares. This follows the approval of the scheme by Mayne Pharma shareholders in June 2025. The hearing is scheduled for October 22, 2025, at the Supreme Court of New South Wales. Shareholders have the right to appear and oppose the scheme if desired. This acquisition could significantly impact Mayne Pharma’s operations and market positioning, potentially affecting stakeholders involved.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has announced a favorable outcome in its legal proceedings with Cosette Pharmaceuticals, Inc., regarding the proposed acquisition by Cosette. The Supreme Court of New South Wales ruled in favor of Mayne Pharma, dismissing Cosette’s claims. The company will proceed with the acquisition scheme, which is subject to certain conditions, including FIRB and court approvals. The scheme is expected to become effective on 23 October 2025, with shareholders receiving $7.40 per share on or around 3 November 2025. This development marks a significant step forward in Mayne Pharma’s strategic acquisition plans, potentially enhancing its market position and shareholder value.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma’s Annual Report for 2025 highlights the company’s dedication to enhancing patient access to medications through innovation and accessibility. This commitment is expected to strengthen their market position and positively impact stakeholders by ensuring the availability of better and safer medicines.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has released its 2025 Corporate Governance Statement, emphasizing its adherence to the ASX Corporate Governance Principles and Recommendations. The Board of Directors is committed to guiding the company with a focus on shareholder interests, risk management, and ethical conduct. The statement highlights the company’s comprehensive governance policies, including a Business Code of Conduct and various committee charters, which are available on its website. This release underscores Mayne Pharma’s dedication to updating its governance practices in line with evolving standards, potentially strengthening its industry position and stakeholder trust.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited announced the cessation of certain securities, specifically 529,129 performance rights and 695,322 options, due to the expiry of options or other convertible securities without exercise or conversion as of September 30, 2025. This cessation may impact the company’s capital structure and could have implications for stakeholders, as it reflects adjustments in the company’s financial instruments and potential changes in shareholder value.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma announced that its oral contraceptive, NEXTSTELLIS®, has been approved for reimbursement by the Australian Pharmaceutical Benefits Scheme (PBS), effective from October 1, 2025. This listing is expected to enhance access to contraceptive options in Australia, aligning with recommendations to improve access to newer hormonal contraceptives. NEXTSTELLIS® is notable for being the first contraceptive pill containing estetrol (E4), a natural estrogen, derived from a plant source. The PBS listing significantly reduces the cost for patients, making it more affordable and accessible, which is a positive development for women’s healthcare in Australia.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group has announced that First Sentier Investors (Australia) IM Ltd has ceased to be a substantial holder in the company as of September 23, 2025. This change in substantial holding could impact the company’s shareholder structure and influence its market perception, as substantial holders often play a significant role in corporate governance and strategic decisions.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma addresses recent media reports concerning objections to its Scheme transaction with Cosette, particularly regarding the potential closure of its Salisbury manufacturing site. The company clarifies that it has no plans to close the site and highlights its recent financial performance and facility upgrades. Mayne Pharma is seeking further information and considering direct communication with the Foreign Investment Review Board (FIRB) to ensure all necessary information is available for informed decision-making regarding the Scheme.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Ltd is an ASX-listed specialty pharmaceutical company focused on commercializing branded women’s health and dermatology pharmaceuticals, with a strong track record in developing oral drug delivery systems. The company’s latest financial report for the year ending June 30, 2025, highlights a 5.1% increase in revenue from continuing operations, reaching $408.1 million, and a 13% rise in gross profit to $247.3 million. Despite these gains, the company reported a net loss after tax of $90.1 million, an improvement from the previous year’s loss of $168.6 million. Key financial metrics include an adjusted EBITDA of $47 million, up from $22.9 million in the previous year, and a reported EBITDA of $18.4 million, a significant turnaround from a loss of $92.5 million in 2024. The company also announced strategic moves, including the acquisition of US rights to TWYNEO® and EPSOLAY®, and is navigating a proposed acquisition by Cosette Pharmaceuticals, which is currently under court review. Looking forward, Mayne Pharma aims to drive growth in its Women’s Health and Dermatology segments, leveraging recent investments and strategic partnerships to enhance its market position.
Mayne Pharma Group Limited has released its FY25 results, highlighting the company’s financial performance and operational achievements. The presentation emphasizes non-IFRS financial measures such as EBITDA to provide a clearer picture of its underlying business performance. This approach aims to offer stakeholders a meaningful comparison of results over different periods, despite the presence of non-audited financial information. The announcement underscores the company’s commitment to transparency and its strategic focus on maintaining robust operational performance amidst changing market conditions.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited reported a 5% increase in revenue to $408.1 million and a substantial 105% rise in underlying EBITDA to $47.0 million for the fiscal year ending June 30, 2025. The company’s financial performance was bolstered by improved cash flow from continuing operations, which surged by 460% to $45.4 million. This growth reflects the company’s strategic focus on its women’s health and dermatology businesses, which benefited from effective channel management and targeted initiatives. Despite a net loss after tax of $90.1 million, the results indicate a positive trajectory in operational efficiency and market engagement.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
Mayne Pharma Group Limited has received a notice from Cosette Pharmaceuticals alleging a breach of their scheme implementation deed (SID) due to misleading conduct and disclosure issues related to an FDA Untitled Letter. Mayne Pharma disputes these claims, asserting that all necessary information has been disclosed and intends to reject any termination notice from Cosette as invalid, while reserving its rights to enforce the SID through legal proceedings.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.